Jiangxi Starry Pharmaceutical Co., Ltd.

Jiangxi Starry Pharmaceutical Co., Ltd. was founded in January 2011, located in Zhangshu City salt chemical industrial base, covers an area of 300 mu (a Chinese unit). We are a national high-tech enterprise engaged in the research and development, manufacturing and sales of X-CT contrast medium intermediates, nuclear magnetic resonance APIs and CMO products. We have more than 300 employees, with a registered capital of 68 million yuan, and is a holding subsidiary of Zhejiang Starry Pharmaceutical Co., Ltd(Stock code: 603520).

Upholding the creed "Innovation-driven development", we have a more complete technical management and research and development system. Under the guidance of the quality concept of "Quality is life, quality is guaranteed", our company has built a high-level comprehensive quality testing center, with a professional talent team, advanced equipment from Japan and the United States, scientific testing methods and high compliance management software, strict product quality control, to create an advanced quality of the enterprise advantage. Adhering to the green and circular development, we have invested in the construction of sewage treatment stations and launched RTO projects to improve wastewater and waste gas treatment capacity. For the province's waste gas treatment beneficial exploration to ensure that enterprises achieve safe development, green rise. This is a useful exploration for the province's waste gas treatment to ensure that enterprises achieve safe and green development.

In R&D, we have made remarkable achievements: Yichun City “Top Ten Science and Technology Team”, 1 provincial enterprise technology centre, 1 post-doctoral innovation practice base, and have declared a number of patents for inventions. Our development is based on Jiangxi Province, and we have won the tax contribution award of Zhangshu City continuously. Our products are exported to Japan, France and other well-known pharmaceutical companies, the market expanded to Europe, North America, South America and other regions, and we have established a continuous good relationship with domestic and foreign customers.

In 2018, we entered into a strategic cooperation with Guerbet (France), one of the four major international contrast agent original research and development enterprises, which gives our company a unique advantage and strong competitiveness in the field of upstream products of contrast agents. In 2022, our company passed the Customs AEO advanced certification, which gave our products exporting to the international market. In February 2024, our company's research and development of Gadobenate dimeglumine API has been granted with the API registration approval.

Looking to the future, we will continue to practice the theme concept of “GATHERING LIFE ENERGY AND CARING FOR HUMAN HEALTH”, based on the domestic, looking at the world, and constantly bigger and stronger, and strive to build the company into a unique, sustainable, competitive pharmaceutical manufacturing company in Jiangxi and even the country!

BACK